Insmed Inc
NASDAQ:INSM
Net Margin
Insmed Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Insmed Inc
NASDAQ:INSM
|
17.6B USD |
-266%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
344.4B USD |
7%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
161.3B USD |
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
142.6B USD |
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
123.5B USD |
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
117.4B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.6B USD |
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
42B USD |
-11%
|
Insmed Inc
Glance View
Insmed Inc., a biopharmaceutical company rooted in Bridgewater, New Jersey, emerged from the desire to tackle serious and rare diseases with potentially groundbreaking therapies. The company's journey is defined by its commitment to developing novel treatments for patients suffering from conditions often overlooked by mainstream pharmaceutical firms. At the heart of Insmed's operations lies its pursuit of treatments for rare pulmonary diseases, with its flagship product, ARIKAYCE, exemplifying their mission in action. Approved by the FDA for treating Mycobacterium avium complex (MAC) lung disease, ARIKAYCE represents a significant breakthrough, addressing a critical unmet medical need. By targeting specific patient populations with limited options, Insmed taps into niche markets where they face less competition and, simultaneously, a profound opportunity to make a meaningful impact on patient lives. The company's strategy revolves around leveraging innovative science to build a pipeline rich with potential treatments across various stages of clinical development. It focuses on expanding the use of ARIKAYCE, while also exploring new formulations and indications. Insmed channels resources into research and development, securing patent protections and establishing a robust global presence to ensure its therapies reach the patients who need them. Revenues are primarily generated through product sales, with ARIKAYCE as the cornerstone, alongside strategic partnerships and collaborations that allow for shared expertise and resources. This business model positions Insmed not only as a healthcare provider but as a key player in the biopharmaceutical industry, striving to transform lives by bringing forth meaningful medical innovations.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Insmed Inc's most recent financial statements, the company has Net Margin of -265.9%.
You don't have any saved screeners yet